JOURNEY MEDICAL CORP (DERM) Stock Fundamental Analysis
NASDAQ:DERM • US48115J1097
8.17 USD
-0.54 (-6.2%)
At close: Feb 27, 2026
8.17 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM
Taking everything into account, DERM scores 3 out of 10 in our fundamental rating. DERM was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of DERM have multiple concerns. While showing a medium growth rate, DERM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year DERM has reported negative net income.
- DERM had a negative operating cash flow in the past year.
- DERM had negative earnings in 4 of the past 5 years.
- In multiple years DERM reported negative operating cash flow during the last 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -10.17%, DERM is in the better half of the industry, outperforming 67.71% of the companies in the same industry.
- With a decent Return On Equity value of -33.45%, DERM is doing good in the industry, outperforming 61.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.17% | ||
| ROE | -33.45% | ||
| ROIC | N/A |
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of DERM (64.40%) is better than 73.96% of its industry peers.
- DERM's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for DERM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
2. Health
2.1 Basic Checks
- DERM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for DERM has been increased compared to 1 year ago.
- Compared to 5 years ago, DERM has more shares outstanding
- Compared to 1 year ago, DERM has a worse debt to assets ratio.
2.2 Solvency
- DERM has an Altman-Z score of 1.35. This is a bad value and indicates that DERM is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of 1.35, DERM perfoms like the industry average, outperforming 57.81% of the companies in the same industry.
- A Debt/Equity ratio of 0.75 indicates that DERM is somewhat dependend on debt financing.
- DERM has a Debt to Equity ratio of 0.75. This is in the lower half of the industry: DERM underperforms 68.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.35 |
ROIC/WACCN/A
WACC9.41%
2.3 Liquidity
- DERM has a Current Ratio of 1.42. This is a normal value and indicates that DERM is financially healthy and should not expect problems in meeting its short term obligations.
- DERM has a worse Current ratio (1.42) than 71.88% of its industry peers.
- DERM has a Quick Ratio of 1.12. This is a normal value and indicates that DERM is financially healthy and should not expect problems in meeting its short term obligations.
- DERM has a Quick ratio of 1.12. This is in the lower half of the industry: DERM underperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- DERM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.41%, which is quite impressive.
- Looking at the last year, DERM shows a small growth in Revenue. The Revenue has grown by 2.82% in the last year.
- Measured over the past years, DERM shows a quite strong growth in Revenue. The Revenue has been growing by 9.96% on average per year.
EPS 1Y (TTM)41.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
Revenue 1Y (TTM)2.82%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%20.52%
3.2 Future
- The Earnings Per Share is expected to grow by 48.50% on average over the next years. This is a very strong growth
- DERM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.53% yearly.
EPS Next Y52%
EPS Next 2Y50.08%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue Next Year13.98%
Revenue Next 2Y33.27%
Revenue Next 3Y39.53%
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for DERM. In the last year negative earnings were reported.
- The Price/Forward Earnings ratio is 31.72, which means the current valuation is very expensive for DERM.
- 72.40% of the companies in the same industry are more expensive than DERM, based on the Price/Forward Earnings ratio.
- DERM's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.06.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 31.72 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- DERM's earnings are expected to grow with 48.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.08%
EPS Next 3Y48.5%
5. Dividend
5.1 Amount
- DERM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
8.17
-0.54 (-6.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-19 2026-03-19/amc
Inst Owners40.23%
Inst Owner Change26.67%
Ins Owners15.49%
Ins Owner Change9.51%
Market Cap222.71M
Revenue(TTM)59.40M
Net Income(TTM)-8.66M
Analysts82
Price Target13.77 (68.54%)
Short Float %12.55%
Short Ratio19.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-67.58%
Min EPS beat(2)-85.76%
Max EPS beat(2)-49.39%
EPS beat(4)2
Avg EPS beat(4)-12.79%
Min EPS beat(4)-85.76%
Max EPS beat(4)58.28%
EPS beat(8)2
Avg EPS beat(8)-31.88%
EPS beat(12)4
Avg EPS beat(12)26.25%
EPS beat(16)5
Avg EPS beat(16)-0.28%
Revenue beat(2)0
Avg Revenue beat(2)-4.89%
Min Revenue beat(2)-8.32%
Max Revenue beat(2)-1.46%
Revenue beat(4)1
Avg Revenue beat(4)-2.25%
Min Revenue beat(4)-8.32%
Max Revenue beat(4)6.86%
Revenue beat(8)2
Avg Revenue beat(8)-1.81%
Revenue beat(12)4
Avg Revenue beat(12)5.69%
Revenue beat(16)5
Avg Revenue beat(16)1.83%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-243.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-52.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 31.72 | ||
| P/S | 3.75 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.6 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.58
EYN/A
EPS(NY)0.26
Fwd EY3.15%
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS2.18
BVpS0.95
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.17% | ||
| ROE | -33.45% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.4% | ||
| FCFM | N/A |
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 1.35 |
F-Score5
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)346.04%
Cap/Depr(5y)304.38%
Cap/Sales(3y)20.06%
Cap/Sales(5y)15.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
EPS Next Y52%
EPS Next 2Y50.08%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue 1Y (TTM)2.82%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%20.52%
Revenue Next Year13.98%
Revenue Next 2Y33.27%
Revenue Next 3Y39.53%
Revenue Next 5YN/A
EBIT growth 1Y44.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year111.72%
EBIT Next 3Y84.38%
EBIT Next 5YN/A
FCF growth 1Y-246.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.93%
OCF growth 3YN/A
OCF growth 5YN/A
JOURNEY MEDICAL CORP / DERM FAQ
What is the ChartMill fundamental rating of JOURNEY MEDICAL CORP (DERM) stock?
ChartMill assigns a fundamental rating of 3 / 10 to DERM.
Can you provide the valuation status for JOURNEY MEDICAL CORP?
ChartMill assigns a valuation rating of 3 / 10 to JOURNEY MEDICAL CORP (DERM). This can be considered as Overvalued.
What is the profitability of DERM stock?
JOURNEY MEDICAL CORP (DERM) has a profitability rating of 2 / 10.